Table 1 Patient and primary tumor characteristics
From: Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers
Age at diagnosis (years) | Total (n = 63) | |||
|---|---|---|---|---|
Characteristics | < 35 (n = 16) no. (%) | 35–44 (n = 28) no. (%) | ≥ 45 (n = 19) no. (%) | No. (%) |
Age in years, median (range) | 42 (25–49) | |||
Follow-up in months, median (range) | 44 (8–168) | |||
Ethnicity | ||||
Chinese | 6 (37.5) | 13 (46.4) | 9 (47.4) | 28 (44.4) |
Korean | 7 (43.8) | 10 (35.7) | 5 (26.3) | 22 (34.9) |
Malay | 0 | 3 (10.7) | 5 (26.3) | 8 (12.7) |
Indian | 2 (12.5) | 0 | 0 | 2 (3.2) |
Others | 1 (6.3) | 2 (7.1) | 0 | 3 (4.8) |
AJCC stage | ||||
0 | 0 | 0 | 1 (5.3) | 1 (1.6) |
I | 0 | 1 (3.6) | 1 (5.3) | 2 (3.2) |
II | 5 (31.3) | 11 (39.3) | 10 (52.6) | 26 (41.3) |
III | 10 (62.5) | 16 (57.1) | 7 (36.8) | 33 (52.4) |
Unknown (TxN1M0) | 1 (6.3) | 0 | 0 | 1 (1.6) |
Grade | ||||
1 | 0 | 0 | 0 | 0 |
2 | 6 (37.5) | 11 (39.3) | 6 (31.6) | 23 (36.5) |
3 | 10 (62.5) | 16 (57.1) | 13 (68.4) | 39 (61.9) |
Unknown | 0 | 1 (3.6) | 0 | 1 (1.6) |
ER status at diagnosis | ||||
Positive | 9 (56.3) | 19 (67.9) | 8 (42.1) | 36 (57.1) |
Negative | 7 (43.8) | 9 (32.1) | 11 (57.9) | 27 (42.9) |
PR status at diagnosis | ||||
Positive | 7 (43.8) | 13 (46.4) | 7 (36.8) | 27 (42.9) |
Negative | 9 (56.3) | 15 (53.6) | 12 (63.2) | 36 (57.1) |
HER2 status at diagnosis | ||||
Positive | 4 (25.0) | 11 (39.3) | 6 (31.6) | 21 (33.3) |
Negative | 12 (75.0) | 17 (60.7) | 13 (68.4) | 42 (66.7) |
Immunohistochemical subtype | ||||
“Luminal” (ER and/or PR + , HER2−) | 7 (43.8) | 13 (46.4) | 7 (36.8) | 27 (42.9) |
HER2-overexpressing (regardless of ER/PR) | 4 (25.0) | 11 (39.3) | 6 (31.6) | 21 (33.4) |
Triple-negative (ER−, PR−, HER2−) | 5 (31.3) | 4 (14.3) | 6 (31.6) | 15 (23.8) |
Histology | ||||
Ductal | 15 (93.8) | 25 (89.3) | 15 (78.9) | 55 (87.3) |
Lobular | 0 | 0 | 2 (10.5) | 2 (3.2) |
Others | 1 (6.3) | 3 (10.8) | 2 (10.6) | 6 (9.6) |
Adjuvant/neoadjuvant chemotherapy | ||||
No | 0 | 3 (10.7) | 4 (21.1) | 7 (11.1) |
Yes | 16 (100) | 25 (89.3) | 15 (78.9) | 56 (88.9) |
Adjuvant/neoadjuvant anti-HER2 therapy (among HER2 +) | ||||
No | 0 | 1 (9.1) | 1 (16.7) | 2 (9.5) |
Yes | 4 (100) | 10 (90.9) | 5 (83.3) | 19 (90.5) |
Adjuvant/neoadjuvant endocrine therapy (among ER + and/or PR +) | ||||
No | 0 | 3 (15.8) | 2 (22.2) | 5 (13.5) |
Yes | 9 (100) | 16 (84.2) | 7 (77.8) | 32 (86.5) |
